• Explore /
  • Poster
  • / Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor).

Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor).

Abstract Poster

Authors

null

Suhail M. Ali

Lebanon VAMC, Lebanon, PA

Suhail M. Ali , Albert Reising , Kim Leitzel , Joseph J. Drabick , Cristina I. Truica , Monali K. Vasekar , Harry Menon , Vinod Nagabhairu , Hyma Vani Polimera , Neha Pancholy , Prashanth Reddy Moku , Ashok Maddukuri , Herbert Schmid , Wei He , John Millholland , Meredith Lavin , Scott J. Hofsess , Robert William Sweetman , Gabriel N. Hortobagyi , Allan Lipton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1067)

DOI

10.1200/JCO.2020.38.15_suppl.1067

Abstract #

1067

Poster Bd #

152

Abstract Disclosures

Similar Posters

First Author: Francis Arena

First Author: Erica L. Mayer

First Author: Po-Ju Lin

First Author: Ashok Maddukuri